Printer Friendly

CELGENE APPOINTS JAMES A. ROMESSER VICE-PRESIDENT OF RESEARCH AND DEVELOPMENT

 CELGENE APPOINTS JAMES A. ROMESSER VICE-PRESIDENT
 OF RESEARCH AND DEVELOPMENT
 WARREN, N.J., July 1 /PRNewswire/ -- Celgene Corporation (NASDAQ: CELG) today announced the appointment of James A. Romesser, Ph.D., as vice-president of Research and Development - Biotreatment Systems, a newly created position.
 "Jim Romesser will be a tremendous asset to Celgene," said John Ufheil, chairman, president and chief executive officer. "His extensive scientific background and technical management experience will contribute greatly to our research and development of practical systems to treat hazardous wastes."
 Romesser joins Celgene after fourteen years at DuPont Company in Central Research and Development where he held various positions. Most recently, Romesser was responsible for DuPont's Environmental Biotechnology Program. In that capacity, Romesser managed all aspects of the research, development and application of innovative technologies in bioremediation, bioreclamation, biological treatment processes for wastewater and process streams and environmental diagnostics. Romesser also maintained an active biodegradable plastics research lab. Previously at DuPont, Romesser was a research supervisor and principal investigator of microbiology, studying biodegradation of herbicides and fermentation processes to form specialty chemicals.
 Romesser has authored several articles in prestigious scientific publications. In addition, he holds or has pending patents on biotransformation processes to synthesize specialty chemicals, biodegradation processes to confer herbicide resistance, and environmentally degradable plastics.
 Romesser is a member of the Bio/Environmentally Degradable Polymers Society and the American Society of Microbiology. Romesser received his Ph.D. in Microbiology from the University of Illinois at Urbana.
 Celgene Corporation, based in Warren, N.J., is a chemical biotechnology company engaged in the development of chiral chemicals and proprietary biotreatment systems to degrade hazardous wastes.
 -0- 7/1/92
 /CONTACT: R.G. Holmes, vice president and CFO, of Celgene, 908-271-4102, or Anthony J. Russo of Noonan/Russo Communications, 212-979-9180, for Celgene/
 (CELG) CO: Celgene Corporation ST: New Jersey IN: MTC SU: PER


LR-OS -- NY026 -- 5547 07/01/92 09:49 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 1, 1992
Words:313
Previous Article:JOY AND BISCHOFF TO BE AWARDED U.S. $155 MILLION SCRUBBER CONTRACT
Next Article:DR. MARTIN BARKIN ELECTED DIRECTOR OF DEPRENYL ANIMAL HEALTH
Topics:


Related Articles
Celgene Corporation Names Vice President of Medical Affairs

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters